Masashi Narazaki

List of Publications by Year
in descending order

89 papers	11,572 citations	53751 45 h-index	56687 83 g-index
89 all docs	89 docs citations	89 times ranked	16131 citing authors

#	Article	IF	Citations
1	Current status and prospects of IL-6â€“targeting therapy. Expert Review of Clinical Pharmacology, 2022, 15, 575-592.	1.3	10
2	Increased levels of plasma nucleotides in patients with rheumatoid arthritis. International Immunology, 2021, 33, 119-124.	1.8	11
3	Pulmonary artery hypertension prior to the relapse of adultâ€onset Still's disease. Respirology Case Reports, 2021, 9, e00746.	0.3	1
4	Loss of FCHSD1 leads to amelioration of chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	7
5	Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Annals of the Rheumatic Diseases, 2020, 79, 103-111.	0.5	145
6	A case of SAPHO syndrome with the lesions limited to the skull. Rheumatology Advances in Practice, 2020, 4, rkaa034.	0.3	0
7	Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine, 2020, 217, .	4.2	115
8	Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. Modern Rheumatology Case Reports, 2020, 4, 302-309.	0.3	4
9	Tet DNA demethylase is required for plasma cell differentiation by controlling expression levels of IRF4. International Immunology, 2020, 32, 683-690.	1.8	10
10	The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. Journal of Experimental Medicine, 2019, 216, 1630-1647.	4.2	32
11	Targeting Interleukin-6 Signaling in Clinic. Immunity, 2019, 50, 1007-1023.	6.6	570
12	Anti-receptor activator of nuclear factor Î¹B ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis. International Immunology, 2019, 31, 277-285.	1.8	9
13	Interleukin (IL-6) Immunotherapy. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028456.	2.3	223
14	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences, 2018, 19, 3528.	1.8	143
15	Apoptosis-derived membrane vesicles drive the cGASâ€“STING pathway and enhance type I IFN production in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1507-1515.	0.5	164
16	Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186. Mucosal Immunology, 2017, 10, 446-459.	2.7	55
17	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology, 2017, 13, 535-551.	1.3	166
18	Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis. Annals of the Rheumatic Diseases, 2017, 76, 1440-1448.	0.5	57

#	Article	IF	Citations
19	Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. Scientific Reports, 2017, 7, 16428.	1.6	24
20	IL-6 Superfamily. , 2017, , 573-586.		2
21	Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals. Frontiers in Microbiology, 2017, 8, 238.	1.5	79
22	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. Journal of Scleroderma and Related Disorders, 2017, 2, S20-S28.	1.0	1
23	Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis and Rheumatology, 2016, 68, 2646-2661.	2.9	463
24	Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8, 959-970.	1.0	521
25	LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-Î²B activation. Scientific Reports, 2016, 6, 25738.	1.6	26
26	Regulation of IL-6 in Immunity and Diseases. Advances in Experimental Medicine and Biology, 2016, 941, 79-88.	0.8	135
27	Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nature Communications, 2016, 7, 11205.	5.8	148
28	Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases. , 2015, , 515-525.		0
29	Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. Arthritis and Rheumatology, 2015, 67, 1481-1490.	2.9	79
30	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern Rheumatology, 2015, 25, 134-137.	0.9	26
31	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Seminars in Immunology, 2014, 26, 88-96.	2.7	144
32	Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: Graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering. European Journal of Dermatology, 2014, 24, 101-103.	0.3	2
33	IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014, 6, a016295-a016295.	2.3	2,943
34	Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 253-259.	0.6	33
35	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern Rheumatology, 2013, , 1.	0.9	12
36	Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S9282.	0.4	12

#	Article	IF	Citations
37	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. Inflammation and Regeneration, 2013, 33, 054-065.	1.5	13
38	A case of BehÃ§etâ€™s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology, 2012, 22, 298-302.	0.9	97
39	572â€ƒEffect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis. World Allergy Organization Journal, 2012, 5, S181.	1.6	0
40	Therapeutic Targeting of the Interleukin-6 Receptor. Annual Review of Pharmacology and Toxicology, 2012, 52, 199-219.	4.2	240
41	A case of BehÃ§etâ€™s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology, 2012, 22, 298-302.	0.9	64
42	Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review. Current Rheumatology Reviews, 2012, 8, 209-226.	0.4	4
43	Antiâ€interleukinâ€6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Letters, 2011, 585, 3699-3709.	1.3	123
44	Tocilizumab, a humanized antiâ€interleukinâ€6 receptor antibody, for the treatment of autoimmune disorders. Drug Development Research, 2011, 72, 717-732.	1.4	1
45	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	0.9	15
46	Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1. Annals of the Rheumatic Diseases, 2011, 70, 1164-1165.	0.5	79
47	Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology, 2011, 50, 1344-1346.	0.9	115
48	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	0.9	12
49	Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood, 2010, 116, 3099-3107.	0.6	6
50	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 2010, 49, 2408-2412.	0.9	177
51	Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2010, 6, 843-854.	1.3	70
52	Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology, 2010, 49, 824-826.	0.9	21
53	Minimal influence of tocilizumab on IFN-Î³ synthesis by tuberculosis antigens. Modern Rheumatology, 2010, 20, 130-133.	0.9	25
54	Minimal influence of tocilizumab on IFN-Î³ synthesis by tuberculosis antigens. Modern Rheumatology, 2010, 20, 130-133.	0.9	20

#	Article	IF	Citations
55	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial. International Archives of Allergy and Immunology, 2009, 149, 359-368.	0.9	41
56	Preventative Effect of a Flavonoid, Enzymatically Modified Isoquercitrin on Ocular Symptoms of Japanese Cedar Pollinosis. Allergology International, 2009, 58, 373-382.	1.4	40
57	Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint Bone Spine, 2009, 76, 105-107.	0.8	13
58	Successful treatment of reactive arthritis with a humanized antiâ€“interleukinâ€6 receptor antibody, tocilizumab. Arthritis and Rheumatism, 2009, 61, 1762-1764.	6.7	69
59	Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Annals of the Rheumatic Diseases, 2009, 68, 1235-1236.	0.5	72
60	Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Modern Rheumatology, 2009, 19, 522-529.	0.9	16
61	What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al. Arthritis and Rheumatism, 2008, 59, 601-601.	6.7	4
62	Neuropilin-2: A New Molecular Target for Antiangiogenic and Antitumor Strategies. Journal of the National Cancer Institute, 2008, 100, 81-83.	3.0	9
63	Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A. Blood, 2008, 111, 4126-4136.	0.6	51
64	Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood, 2006, 107, 3892-3901.	0.6	74
65	Conflicting Results from Clinical Observations and Murine Models: What Is the Role of Plasminogen Activators in Tumor Growth?. Journal of the National Cancer Institute, 2006, 98, 726-727.	3.0	1
66	Tumor Cell Populations Differ in Angiogenic Activity: A Model System for Spontaneous Angiogenic Switch Can Tell Us Why. Journal of the National Cancer Institute, 2006, 98, 294-295.	3.0	11
67	Canstatin: an inhibitor of angiogenesis and tumor growth revisited. Cancer Journal (Sudbury, Mass), 2006, 12, 110-2.	1.0	4
68	Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1Î± in the circulation. Blood, 2005, 105, 4561-4568.	0.6	93
69	Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies. Journal of the National Cancer Institute, 2005, 97, 705-707.	3.0	16
70	Differential processing of stromal-derived factor-1Î± and stromal-derived factor-1Î² explains functional diversity. Blood, 2004, 103, 2452-2459.	0.6	192
71	SOCS-1/SSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN-Î³ and IL-4 Signaling In Vivo. Immunity, 2001, 14, 535-545.	6.6	176
72	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcomaâ€“associated herpesvirus. Blood, 2001, 98, 3042-3049.	0.6	68

#	Article	IF	Citations
73	Viral Interleukin 6 Stimulates Human Peripheral Blood B Cells That Are Unresponsive to Human Interleukin 6. Cellular Immunology, 2001, 212, 118-125.	1.4	19
74	Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation. Journal of Experimental Medicine, 2001, 193, 263-270.	4.2	138
75	Defective Thymocyte Development and Perturbed Homeostasis of T cells in STAT-Induced STAT Inhibitor-1/Suppressors of Cytokine Signaling-1 Transgenic Mice. Journal of Immunology, 2000, 165, 1799-1806.	0.4	73
76	Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha -induced cell death in fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5405-5410.	3.3	179
77	IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN-Î³. Journal of Immunology, 2000, 164, 5833-5843.	0.4	83
78	Negative-feedback Regulations Of Cytokine Signals. , 2000, , .		0
79	Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13130-13134.	3.3	226
80	Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 America, 1998, 95, 15577-15582.	3.3	272
81	Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3. Biochemical and Biophysical Research Communications, 1997, 237, 79-83.	1.0	164
82	Overlapping and distinct signals through leptin receptor (OB-R) and a closely related cytokine signal transducer, gp130. FEBS Letters, 1997, 401, 49-52.	1.3	44
83	Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6. FEBS Letters, 1997, 401, 133-137.	1.3	31
84	Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130. FEBS Letters, 1997, 403, 79-82.	1.3	72
85	Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997, 387, 924-929.	13.7	1,224
86	Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy. Journal of Biological Chemistry, 1996, 271, 9535-9545.	1.6	344
87	Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10998-11001.	3.3	197
88	Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunology Letters, 1992, 31, 123-130.	1.1	70
89	The Molecular Biology of Interleukin 6 and its Receptor. Novartis Foundation Symposium, 1992, 167, 5-23.	1.2	32